TYRA BIOSCIENCES, INC. TYRA 深 滬
等待開盤 11-07 09:30:00 美东时间
14.28
-0.540
-3.64%
華盛通- 最 高15.38
- 今 開14.73
- 成交量 21.50万股
- 最 低 13.35
- 昨 收 14.82
- 總市值 7.61亿
- 52周最高 17.27
- 市盈率 靜 --
- 換手率 0.40%
- 52周最低 6.42
- 委 比 72.94%
- 總股本 5329.71万
- 歷史最高 31.36
- 量 比 0.84
- 振 幅 13.70%
- 歷史最低 4.93
- 每 手 1
- 風險率 2.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tyra Biosciences Q3 EPS $(0.50), Inline
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.50) per share which met the analyst consensus estimate. This is a 21.95 percent decrease over losses of $(0.41) per share from the same period last year.
11-06 05:48
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
Raymond James Initiates Coverage On Tyra Biosciences with Strong Buy Rating, Announces Price Target of $35
Raymond James analyst Chris Raymond initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a Strong Buy rating and announces Price Target of $35.
09-04 00:54
Tyra Biosciences Doses First Child In Phase 2 Trial Of Dabogratinib, First Oral FGFR3 Inhibitor For Achondroplasia
-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia--Initial results from safety sentinel cohort expected in 2H 2026-CARLSBAD, Calif., Aug. 21, 2025 /PRNewswire/ -- Tyra
08-21 20:12
Tyra Biosciences Q2 EPS $(0.47) Beats $(0.53) Estimate
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.53) by 11.15 percent. This is a 46.87 percent decrease over losses of $(0.32) per share from
08-15 04:37
Tyra Biosciences Says Late-Breaking Abstract On TYRA-300 Preclinical Results Accepted For Presentation At ENDO 2025
Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR)
07-09 04:09
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $30 price target.
07-01 19:37
Tyra Biosciences Independent Director Gilla Kaplan Sells 58% Of Holding
Some Tyra Biosciences, Inc. (NASDAQ:TYRA) shareholders may be a little concerne...
06-19 18:54
